All In Biotech

Drug Trial Radar · NCT06187402

A Study of LM-24C5 For Advanced Solid Tumors

A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Jun 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Jan 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-24C5Drug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 60 weeks
  2. Incidence of dose-limiting toxicity (DLT)Time frame: 60 weeks
  3. Incidence of serious adverse event (SAE)Time frame: 60 weeks
  4. Ear TemperatureTime frame: 60 weeks
  5. Pulse in BPM(Beat per Minute)Time frame: 60 weeks
  6. Blood Pressure in mmHg (Both Systolic and Diastolic blood pressure)Time frame: 60 weeks
  7. Number of participants with abnormal Hematology test resultsTime frame: 60 weeks
  8. Number of participants with abnormal Urinalysis test resultsTime frame: 60 weeks
  9. Number of participants with abnormal Blood Biochemistry test resultsTime frame: 60 weeks
  10. Number of participants with abnormal Coagulation test results in PT(Prothrombin time), APTT(Activated partial thromboplastin time), FIB(Fibrinogen), TT(Thrombin time) and INR(International normalized ratio).Time frame: 60 weeks
  11. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 60 weeks
  12. 12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.Time frame: 60 weeks
  13. ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 60 weeks
  14. Overall Response Rate (ORR)Time frame: 36 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Southern California (USC) - Norris Comprehensive Cancer Center

    Los Angeles, California · Not yet recruiting

  • Ocala Oncology

    Ocala, Florida · Recruiting

  • Indiana University Melvan and Bren Simon Cancer Center

    Indianapolis, Indiana · Not yet recruiting

  • The Christ Hospital

    Cincinnati, Ohio · Not yet recruiting

  • Mary Crowley Cancer Research Center

    Dallas, Texas · Not yet recruiting

  • Virginia Cancer Specialists, P.C.

    Fairfax, Virginia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.